title: Reappraising the use of β-lactams to treat tuberculosis.
abstract: The emergence of multidrug-resistant and extensively drug-resistant tuberculosis calls for novel approaches to treatment. Recent studies have shown that BlaC, the β-lactamase of Mycobacterium tuberculosis, is the major determinant of β-lactam resistance. This review invites the reader to explore evidence in order to answer the questions: can β-lactam and β-lactamase inhibitors adequately treat M. tuberculosis infection and are they a viable option in the management of resistant tuberculosis today?
authors.affiliation: Division of Pulmonary, Critical Care and Sleep Medicine, University Hospitals Case Medical Center and Louis Stokes Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA.
authors.forename: Sebastian G
authors.initials: SG
authors.lastname: Kurz
authors.forename: Robert A
authors.initials: RA
authors.lastname: Bonomo
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry; D002473:Cell Wall / Q000187:drug effects; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000737:chemistry; D047090:beta-Lactams / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000995:Antitubercular Agents; D001426:Bacterial Proteins; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams; D001618:beta-Lactamases